Current treatment strategy for metastatic
ALK+
NSCLC
- Next generation ALK TKI
- Combination therapy, e.g.
- Alectinib + atezolizumab
- Alectinib + bevacizumab
- Alectinib + cobimetinib
Therapy
Are there better 1L options?
2nd generation ALK TKI
PD
2
L
Crizotinib
1L
INDICACIÓN NO APROBADA, EN INVESTIGACIÓN
